Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) Research & Development (2017 - 2025)

Cue Biopharma's Research & Development history spans 9 years, with the latest figure at $4.8 million for Q3 2025.

  • For Q3 2025, Research & Development fell 49.33% year-over-year to $4.8 million; the TTM value through Sep 2025 reached $28.4 million, down 29.01%, while the annual FY2024 figure was $36.3 million, 11.05% down from the prior year.
  • Research & Development for Q3 2025 was $4.8 million at Cue Biopharma, down from $7.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $11.5 million in Q4 2021 and bottomed at $4.8 million in Q3 2025.
  • The 5-year median for Research & Development is $9.6 million (2022), against an average of $9.4 million.
  • The largest annual shift saw Research & Development soared 50.17% in 2021 before it crashed 49.33% in 2025.
  • A 5-year view of Research & Development shows it stood at $11.5 million in 2021, then dropped by 1.3% to $11.3 million in 2022, then fell by 3.93% to $10.9 million in 2023, then tumbled by 34.01% to $7.2 million in 2024, then tumbled by 33.83% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Research & Development are $4.8 million (Q3 2025), $7.9 million (Q2 2025), and $8.5 million (Q1 2025).